A citation-based method for searching scientific literature

Guangwu Guo, Juliann Chmielecki, Chandra Goparaju, Adriana Heguy, Igor Dolgalev, Michele Carbone, Sara Seepo, Matthew Meyerson, Harvey I Pass. Cancer Res 2015
Times Cited: 196







List of co-cited articles
1115 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
Raphael Bueno, Eric W Stawiski, Leonard D Goldstein, Steffen Durinck, Assunta De Rienzo, Zora Modrusan, Florian Gnad, Thong T Nguyen, Bijay S Jaiswal, Lucian R Chirieac,[...]. Nat Genet 2016
455
71

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Julija Hmeljak, Francisco Sanchez-Vega, Katherine A Hoadley, Juliann Shih, Chip Stewart, David Heiman, Patrick Tarpey, Ludmila Danilova, Esther Drill, Ewan A Gibb,[...]. Cancer Discov 2018
258
49

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Matthew Bott, Marie Brevet, Barry S Taylor, Shigeki Shimizu, Tatsuo Ito, Lu Wang, Jenette Creaney, Richard A Lake, Maureen F Zakowski, Boris Reva,[...]. Nat Genet 2011
461
43

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Nicholas J Vogelzang, James J Rusthoven, James Symanowski, Claude Denham, E Kaukel, Pierre Ruffie, Ulrich Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold,[...]. J Clin Oncol 2003
41

Germline BAP1 mutations predispose to malignant mesothelioma.
Joseph R Testa, Mitchell Cheung, Jianming Pei, Jennifer E Below, Yinfei Tan, Eleonora Sementino, Nancy J Cox, A Umran Dogan, Harvey I Pass, Sandra Trusa,[...]. Nat Genet 2011
634
32

High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
Masaki Nasu, Mitsuru Emi, Sandra Pastorino, Mika Tanji, Amy Powers, Hugh Luk, Francine Baumann, Yu-An Zhang, Adi Gazdar, Shreya Kanodia,[...]. J Thorac Oncol 2015
189
31

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Gérard Zalcman, Julien Mazieres, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Olivier Molinier, Romain Corre, Isabelle Monnet, Valérie Gounant,[...]. Lancet 2016
503
26

Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Marco Lo Iacono, Valentina Monica, Luisella Righi, Federica Grosso, Roberta Libener, Simona Vatrano, Paolo Bironzo, Silvia Novello, Loredana Musmeci, Marco Volante,[...]. J Thorac Oncol 2015
98
23

High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.
Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, Masaki Ohmuraya, Ayuko Sato, Tohru Tsujimura, Seiki Hasegawa, Takashi Nakano, Masaki Nasu, Sandra Pastorino,[...]. Proc Natl Acad Sci U S A 2016
93
22

Novel insights into mesothelioma biology and implications for therapy.
Timothy A Yap, Joachim G Aerts, Sanjay Popat, Dean A Fennell. Nat Rev Cancer 2017
186
21

BAP1 and cancer.
Michele Carbone, Haining Yang, Harvey I Pass, Thomas Krausz, Joseph R Testa, Giovanni Gaudino. Nat Rev Cancer 2013
388
18

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim Aerts, Susana Cedres Perez, Alessandra Bearz, Kristiaan Nackaerts, Dean A Fennell, Dariusz Kowalski, Anne S Tsao,[...]. Lancet Oncol 2017
245
18

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, Sylvie Lantuejoul, Pascal Dô, Olivier Bylicki, Isabelle Monnet, Romain Corre, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez,[...]. Lancet Oncol 2019
228
18

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
Vasiliki Panou, Meghana Gadiraju, Arthur Wolin, Caroline M Weipert, Emily Skarda, Aliya N Husain, Jyoti D Patel, Buerkley Rose, Shannon R Zhang, Madison Weatherly,[...]. J Clin Oncol 2018
87
20

Loss of BAP1 function leads to EZH2-dependent transformation.
Lindsay M LaFave, Wendy Béguelin, Richard Koche, Matt Teater, Barbara Spitzer, Alan Chramiec, Efthymia Papalexi, Matthew D Keller, Todd Hricik, Katerina Konstantinoff,[...]. Nat Med 2015
208
17

Genomic Landscape of Malignant Mesotheliomas.
Shumei Kato, Brett N Tomson, Timon P H Buys, Sheryl K Elkin, Jennifer L Carter, Razelle Kurzrock. Mol Cancer Ther 2016
40
42

A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.
Sandra Pastorino, Yoshie Yoshikawa, Harvey I Pass, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Tomoko Hashimoto-Tamaoki,[...]. J Clin Oncol 2018
66
25

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
Michele Carbone, Prasad S Adusumilli, H Richard Alexander, Paul Baas, Fabrizio Bardelli, Angela Bononi, Raphael Bueno, Emanuela Felley-Bosco, Francoise Galateau-Salle, David Jablons,[...]. CA Cancer J Clin 2019
156
17

Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.
Helen Yu, Helen Pak, Ian Hammond-Martel, Mehdi Ghram, Amélie Rodrigue, Salima Daou, Haithem Barbour, Luc Corbeil, Josée Hébert, Elliot Drobetsky,[...]. Proc Natl Acad Sci U S A 2014
217
16

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Aliya Noor Husain, Thomas V Colby, Nelson G Ordóñez, Timothy Craig Allen, Richard Luther Attanoos, Mary Beth Beasley, Kelly Jo Butnor, Lucian R Chirieac, Andrew M Churg, Sanja Dacic,[...]. Arch Pathol Lab Med 2018
265
16

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Evan W Alley, Juanita Lopez, Armando Santoro, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Emilie van Brummelen. Lancet Oncol 2017
299
16

Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.
Yuna Blum, Clément Meiller, Lisa Quetel, Nabila Elarouci, Mira Ayadi, Danisa Tashtanbaeva, Lucile Armenoult, François Montagne, Robin Tranchant, Annie Renier,[...]. Nat Commun 2019
69
23

BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.
Angela Bononi, Carlotta Giorgi, Simone Patergnani, David Larson, Kaitlyn Verbruggen, Mika Tanji, Laura Pellegrini, Valentina Signorato, Federica Olivetto, Sandra Pastorino,[...]. Nature 2017
206
15

Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
Francine Baumann, Erin Flores, Andrea Napolitano, Shreya Kanodia, Emanuela Taioli, Harvey Pass, Haining Yang, Michele Carbone. Carcinogenesis 2015
140
15

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Josine Quispel-Janssen, Vincent van der Noort, Jeltje F de Vries, Marion Zimmerman, Ferry Lalezari, Erik Thunnissen, Kim Monkhorst, Robert Schouten, Laurel Schunselaar, Maria Disselhorst,[...]. J Thorac Oncol 2018
138
15


Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
Aurélien de Reyniès, Marie-Claude Jaurand, Annie Renier, Gabrielle Couchy, Ilir Hysi, Nabila Elarouci, Françoise Galateau-Sallé, Marie-Christine Copin, Paul Hofman, Aurélie Cazes,[...]. Clin Cancer Res 2014
86
16

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Maria J Disselhorst, Josine Quispel-Janssen, Ferry Lalezari, Kim Monkhorst, Jeltje F de Vries, Vincent van der Noort, Emmy Harms, Sjaak Burgers, Paul Baas. Lancet Respir Med 2019
124
14

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).
Morihito Okada, Takashi Kijima, Keisuke Aoe, Terufumi Kato, Nobukazu Fujimoto, Kazuhiko Nakagawa, Yuichiro Takeda, Toyoaki Hida, Kuninobu Kanai, Fumio Imamura,[...]. Clin Cancer Res 2019
118
14

Functional inactivation of NF2/merlin in human mesothelioma.
Claudio Thurneysen, Isabelle Opitz, Stefanie Kurtz, Walter Weder, Rolf A Stahel, Emanuela Felley-Bosco. Lung Cancer 2009
95
13

Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
Raffit Hassan, Betsy Morrow, Anish Thomas, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Meghana Gadiraju, Vasiliki Panou, Shaojian Gao, Idrees Mian,[...]. Proc Natl Acad Sci U S A 2019
69
18

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Paul Baas, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia,[...]. Lancet 2021
232
13

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Susana Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia, Irene Sansano, Ana Enguita, Alejandro Navarro-Mendivil, Alex Martinez-Marti, Pablo Martinez, Enriqueta Felip. PLoS One 2015
132
12

The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.
Marieke Hylebos, Guy Van Camp, Jan P van Meerbeeck, Ken Op de Beeck. J Thorac Oncol 2016
52
23

Malignant mesothelioma: facts, myths, and hypotheses.
Michele Carbone, Bevan H Ly, Ronald F Dodson, Ian Pagano, Paul T Morris, Umran A Dogan, Adi F Gazdar, Harvey I Pass, Haining Yang. J Cell Physiol 2012
233
12

Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma.
Robin Tranchant, Lisa Quetel, Anne Tallet, Clement Meiller, Annie Renier, Leanne de Koning, Aurelien de Reynies, Francoise Le Pimpec-Barthes, Jessica Zucman-Rossi, Marie-Claude Jaurand,[...]. Clin Cancer Res 2017
45
26

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
Luana Calabrò, Aldo Morra, Diana Giannarelli, Giovanni Amato, Armida D'Incecco, Alessia Covre, Arthur Lewis, Marlon C Rebelatto, Riccardo Danielli, Maresa Altomonte,[...]. Lancet Respir Med 2018
126
12

Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.
Fernando López-Ríos, Shannon Chuai, Raja Flores, Shigeki Shimizu, Takatoshi Ohno, Kazuhiko Wakahara, Peter B Illei, Sanaa Hussain, Lee Krug, Maureen F Zakowski,[...]. Cancer Res 2006
173
11

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.
Aaron Scott Mansfield, Anja C Roden, Tobias Peikert, Yuri M Sheinin, Susan M Harrington, Christopher J Krco, Haidong Dong, Eugene D Kwon. J Thorac Oncol 2014
155
11

High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
A B Bianchi, S I Mitsunaga, J Q Cheng, W M Klein, S C Jhanwar, B Seizinger, N Kley, A J Klein-Szanto, J R Testa. Proc Natl Acad Sci U S A 1995
252
11

The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
Aatur D Singhi, Alyssa M Krasinskas, Haroon A Choudry, David L Bartlett, James F Pingpank, Herbert J Zeh, Alyssa Luvison, Kimberly Fuhrer, Nathan Bahary, Raja R Seethala,[...]. Mod Pathol 2016
78
14

Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.
Haining Yang, Zeyana Rivera, Sandro Jube, Masaki Nasu, Pietro Bertino, Chandra Goparaju, Guido Franzoso, Michael T Lotze, Thomas Krausz, Harvey I Pass,[...]. Proc Natl Acad Sci U S A 2010
176
11

Novel therapies for malignant pleural mesothelioma.
Arnaud Scherpereel, Frederic Wallyn, Steven M Albelda, Camille Munck. Lancet Oncol 2018
82
13

BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
Marta Cigognetti, Silvia Lonardi, Simona Fisogni, Piera Balzarini, Vilma Pellegrini, Andrea Tironi, Luisa Bercich, Mattia Bugatti, Giulio Rossi, Bruno Murer,[...]. Mod Pathol 2015
152
10

Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.
Simion Chiosea, Alyssa Krasinskas, Philip T Cagle, Kisha A Mitchell, Dani S Zander, Sanja Dacic. Mod Pathol 2008
139
10

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P Baas, D Fennell, K M Kerr, P E Van Schil, R L Haas, S Peters. Ann Oncol 2015
194
10

Molecular pathogenesis of malignant mesothelioma.
Yoshitaka Sekido. Carcinogenesis 2013
148
10

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
Luana Calabrò, Aldo Morra, Ester Fonsatti, Ornella Cutaia, Carolina Fazio, Diego Annesi, Marica Lenoci, Giovanni Amato, Riccardo Danielli, Maresa Altomonte,[...]. Lancet Respir Med 2015
127
10

Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.
Aaron S Mansfield, Tobias Peikert, James B Smadbeck, Julia B M Udell, Enrique Garcia-Rivera, Laura Elsbernd, Courtney L Erskine, Virginia P Van Keulen, Farhad Kosari, Stephen J Murphy,[...]. J Thorac Oncol 2019
61
16

Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
Gamze Ugurluer, Kenneth Chang, Mauricio E Gamez, Andrea L Arnett, Ritujith Jayakrishnan, Robert C Miller, Terence T Sio. Anticancer Res 2016
28
35


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.